Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of An
06.03.2018
Share this article
Selexis SA announces that Compugen Ltd. has taken a license to the Selexis SUREtechnology Platform™ for use in generating high-performance research cell banks (RCBs).
All the information you wish to know about this news is accessible here.